AI assistant
Sending…
Skye Bioscience, Inc. — Director's Dealing 2025
Feb 26, 2025
34097_dirs_2025-02-26_4a10c7ba-78ac-4a6f-a6a4-32a597cef18d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2025-02-24
Reporting Person: Diep Tuan Tu (Chief Development Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-24 | Stock Option (Right to Buy) | $2.89 | A | 150000 | Acquired | 2035-02-25 | Common Stock (150000) | Direct |
Footnotes
F1: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025.
More from Skye Bioscience, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Delisting Announcement
2026
May 15
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Board/Management Information
2026
Apr 3
Delisting Announcement
2026
Mar 19
Board/Management Information
2026
Feb 20
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10